KURA
HOLD / NEUTRALMeanRevComposite
51.20
Technical
87.90
Fundamental
39.00
Rank
—
Price
13.59
Hurst
0.26
As of
Aug 26, 2026
Daily
Kura Oncology, Inc.
HealthcareBiotechnologyKura Oncology is a biopharmaceutical company developing cancer treatments based in San Diego. The company markets KOMZIFTI, an oral menin inhibitor, and is advancing darlifarnib through early-stage trials in combination with other therapies for solid tumors. Its pipeline also includes KO-7246 and additional menin inhibitors for both cancer and metabolic disorders.
Market cap
$1.0B
P/E (trailing)
—
P/E (forward)
-5.10
PEG ratio
—
Dividend yield
—
Beta
0.43
52w range
7.36 – 13.90
Return on equity
-167.71%
Profit margin
0.00%
Revenue growth
+36.50%
Earnings growth
—
Price history
1Y: 11.72 (+38.9%) · range 7.40–13.59
Cycle position
53/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 16 · NOT READY · exit proximity 0
Conviction
32/ 100 · maturity 100%
VScore.4035
Buildup.2042
EMA entry setup.2516
Fundamentals.1539
Volume profile
POC
8.87
Price vs POC
+32.1%
Overhead supply
21%
Runway
open sky
Value area 8.55–11.48 · 21% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| short-interest | 0.672 | Sep 14, 2026 |
| squeeze-risk | 0.507 | Sep 14, 2026 |
| trader-sentiment | 0.045 | Sep 2, 2026 |
| earnings-surprise | 0.030 | Sep 10, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -12.79% | +1.45% | 11/20d |
| 40d | -12.79% | +1.45% | 11/40d |